Stockreport

TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to significantly reduce both the signs and symptoms and the progression of structural damage in adults living with active psoria...

Johnson & Johnson  (JNJ) 
Last johnson & johnson earnings: 4/14 06:31 am Check Earnings Report
US:NYSE Investor Relations: jnj.com
PDF Topline results demonstrate efficacy across multiple domains at Week 24, reinforcing TREMFYA ® as a first-line treatment option for patients with active psoriatic arthr [Read more]